Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses (2021 - 2025)

Historic Other Accumulated Expenses for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $20.5 million.

  • Kiniksa Pharmaceuticals International's Other Accumulated Expenses rose 2771.8% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 2771.8%. This contributed to the annual value of $16.1 million for FY2024, which is 9622.85% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Other Accumulated Expenses stood at $20.5 million, which was up 2771.8% from $18.0 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Other Accumulated Expenses high stood at $25.0 million for Q4 2021, and its period low was $4.3 million during Q1 2023.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $16.1 million (2024), whereas its average is $14.8 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 8048.8% in 2023, then surged by 16365.94% in 2024.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Other Accumulated Expenses stood at $25.0 million in 2021, then plummeted by 66.46% to $8.4 million in 2022, then fell by 2.21% to $8.2 million in 2023, then surged by 96.23% to $16.1 million in 2024, then rose by 27.65% to $20.5 million in 2025.
  • Its Other Accumulated Expenses stands at $20.5 million for Q3 2025, versus $18.0 million for Q2 2025 and $17.1 million for Q1 2025.